Product Description
Minoxidil is a common medication prescribed for treating hair loss-related problems. It provides remarkable benefits to patients with hair disorders. To date, the FDA has approved minoxidil only for AGA. However, minoxidil is used off-label for treating several hair disorders as well as increasing body hair growth. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691938/)
Mechanisms of Action: Potassium Channel Activator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Brazil, Germany, Italy, Portugal, Spain, United States
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Alopecia|Alopecia Areata
Phase 2: Ovarian Cancer
Phase 1: Healthy Volunteers|Hypotrichosis|Pain Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| P22112a | P3 |
Not yet recruiting |
Alopecia Areata |
2025-06-01 |
|
| P22112a | P3 |
Unknown Status |
Alopecia |
2025-02-17 |
|
| NCT05272462 | P2 |
Recruiting |
Ovarian Cancer |
2024-12-31 |
|
| SAM-001 | P1 |
Recruiting |
Healthy Volunteers |
2024-12-01 |